Colgate-Palmoliv Q1 FY27 Results (NSE: COLPAL)
Signal: Margin pressure
The read
Q1FY27 delivered a mixed trajectory: top-line momentum sustained at +12% with broad-based domestic growth and premiumisation gains, while gross margin expanded +110bps YoY on cost savings. However, a sharp 33.6% YoY surge in advertising spend (to 15.8% of sales) and a one-off exceptional restructuring charge of ₹3.3 Cr compressed EBITDA margin by ~170bps YoY, making PAT growth (+7%) lag revenue growth. The core oral care volume story remains intact, but the company is clearly choosing to reinvest margin tailwinds into brand building rather than letting operating profit flow through – a deliberate strategy for sustainable market share gains. Net-net, a healthy operational quarter with a cautious eye on margin trajectory.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,590.56 Cr | 12.0% | 0.5% |
| EBIT | ₹465.53 Cr | 7.8% | |
| Net profit | ₹343.08 Cr | 7.0% | |
| EPS | ₹12.61 | 7.0% | |
| EBIT margin | 27.4% |
P&L walk
Standalone company (no subsidiaries); single-segment oral & personal care.
Key positives
- Revenue up 12% YoY driven by high-single-digit volume growth in toothpaste, led by premium and core portfolio.
- Gross margin expanded +110bps YoY to 69.7% on input cost tailwinds and Funding the Growth cost savings.
- A&P investment increased +33.6% YoY, indicating management confidence in demand and willingness to defend market share.
- Excluding one-offs and exceptional items, PAT grew 11% YoY (company reported).
Key concerns
- EBITDA margin contracted ~170bps YoY as A&P spend (15.8% of sales) and other expenses rose faster than revenue.
- PAT growth (+7%) lagged revenue (+12%) even on reported basis; net profit margin declined 110bps YoY to 21.1%.
- Exceptional restructuring charge of ₹3.3 Cr (severance) indicates ongoing organisational changes with potential further costs.
- 3-year sales CAGR of -0.08% and 3-year profit CAGR of -6.44% highlight that the current growth uptick needs sustained confirmation to reverse a weak multi-year trend.
Research and educational content only. Not investment advice.